However, in T1DM, the use of DPP4 inhibitors may have significant clinical consequences, with a reduction in microvascular complications (nephropathy, retinopathy), improvement in quality of life, and social benefits that involve reduced costs associated with hospitalizations and disabilities, especially in populations with preserved residual β function, where early interventions can slow disease progression [20,21]. Here, DPP4 is linked to type 1 diabetes mellitus.